Roche’s competitor to Pfizer’s much-anticipated “good cholesterol” pill torcetrapib may be more powerful than anyone thought, diluting the potential advantage for Pfizer’s most important experimental drug.>>> Discuss This Story
Roche’s competitor to Pfizer’s much-anticipated “good cholesterol” pill torcetrapib may be more powerful than anyone thought, diluting the potential advantage for Pfizer’s most important experimental drug.>>> Discuss This Story
